Literature DB >> 27840227

Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: Issue of the interval between HCC treatment and antiviral therapy.

Pei-Chien Tsai1, Chung-Feng Huang2, Ming-Lung Yu3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27840227     DOI： 10.1016/j.jhep.2016.10.035

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  14 in total

1.  Direct-Acting Antiviral Therapy and Risk of Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C.

Authors:  Chang Hun Lee; In Hee Kim
Journal:  Gut Liver       Date:  2021-05-15       Impact factor: 4.519

Review 2.  Global epidemiology and burden of HCV infection and HCV-related disease.

Authors:  Aaron P Thrift; Hashem B El-Serag; Fasiha Kanwal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-12-07       Impact factor: 46.802

Review 3.  Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?

Authors:  Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2017-02-06

4.  Liver cancer: Effect of HCV clearance with direct-acting antiviral agents on HCC.

Authors:  Josep M Llovet; Augusto Villanueva
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-01       Impact factor: 46.802

5.  Impact of direct-acting antiviral agents on the risk for hepatocellular carcinoma.

Authors:  Xavier Adhoute; Paul Castellani; Marc Bourlière
Journal:  Transl Gastroenterol Hepatol       Date:  2017-12-18

Review 6.  Immunomodulation in hepatocellular cancer.

Authors:  Sunyoung Lee; Matthew Loecher; Renuka Iyer
Journal:  J Gastrointest Oncol       Date:  2018-02

Review 7.  What Comes First: Treatment of Viral Hepatitis or Liver Cancer?

Authors:  Jordan J Feld; Lisette A P Krassenburg
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

8.  Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.

Authors:  George Lau; Yves Benhamou; Guofeng Chen; Jin Li; Qing Shao; Dong Ji; Fan Li; Bing Li; Jialiang Liu; Jinlin Hou; Jian Sun; Cheng Wang; Jing Chen; Vanessa Wu; April Wong; Chris L P Wong; Stella T Y Tsang; Yudong Wang; Leda Bassit; Sijia Tao; Yong Jiang; Hui-Mien Hsiao; Ruian Ke; Alan S Perelson; Raymond F Schinazi
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-07-25

9.  Case report: 8 years after liver transplantation: de novo hepatocellular carcinoma 8 months after HCV clearance through IFN-free antiviral therapy.

Authors:  Giuliano Ramadori; Patrizia Bosio; Federico Moriconi; Ihtzaz A Malik
Journal:  BMC Cancer       Date:  2018-03-06       Impact factor: 4.430

Review 10.  Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan.

Authors:  Saba Khaliq; Syed Mohsin Raza
Journal:  Medicina (Kaunas)       Date:  2018-11-05       Impact factor: 2.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.